144 related articles for article (PubMed ID: 28518105)
41. Synthesis and Evaluation of 64Cu-DOTA-NT-Cy5.5 as a Dual-Modality PET/Fluorescence Probe to Image Neurotensin Receptor-Positive Tumor.
Deng H; Wang H; Wang M; Li Z; Wu Z
Mol Pharm; 2015 Aug; 12(8):3054-61. PubMed ID: 26162008
[TBL] [Abstract][Full Text] [Related]
42. New bifunctional chelator for 64Cu-immuno-positron emission tomography.
Pandya DN; Bhatt N; Dale AV; Kim JY; Lee H; Ha YS; Lee JE; An GI; Yoo J
Bioconjug Chem; 2013 Aug; 24(8):1356-66. PubMed ID: 23883075
[TBL] [Abstract][Full Text] [Related]
43. Development of [⁶⁴Cu]-DOTA-PR81 radioimmunoconjugate for MUC-1 positive PET imaging.
Alirezapour B; Rasaee MJ; Jalilian AR; Rajabifar S; Mohammadnejad J; Paknejad M; Maadi E; Moradkhani S
Nucl Med Biol; 2016 Jan; 43(1):73-80. PubMed ID: 26453525
[TBL] [Abstract][Full Text] [Related]
44. The ionic charge of copper-64 complexes conjugated to an engineered antibody affects biodistribution.
Dearling JL; Paterson BM; Akurathi V; Betanzos-Lara S; Treves ST; Voss SD; White JM; Huston JS; Smith SV; Donnelly PS; Packard AB
Bioconjug Chem; 2015 Apr; 26(4):707-17. PubMed ID: 25719414
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates.
Ait-Mohand S; Fournier P; Dumulon-Perreault V; Kiefer GE; Jurek P; Ferreira CL; Bénard F; Guérin B
Bioconjug Chem; 2011 Aug; 22(8):1729-35. PubMed ID: 21761921
[TBL] [Abstract][Full Text] [Related]
46. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
[TBL] [Abstract][Full Text] [Related]
47. In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector.
Läppchen T; Kiefer Y; Holland JP; Bartholomä MD
Nucl Med Biol; 2018 May; 60():45-54. PubMed ID: 29571066
[TBL] [Abstract][Full Text] [Related]
48. PET Imaging of Dll4 Expression in Glioblastoma and Colorectal Cancer Xenografts Using (64)Cu-Labeled Monoclonal Antibody 61B.
Zhou B; Wang H; Liu R; Wang M; Deng H; Giglio BC; Gill PS; Shan H; Li Z
Mol Pharm; 2015 Oct; 12(10):3527-34. PubMed ID: 26288060
[TBL] [Abstract][Full Text] [Related]
49. Targeting Phosphatidylserine with a
Perreault A; Richter S; Bergman C; Wuest M; Wuest F
Mol Pharm; 2016 Oct; 13(10):3564-3577. PubMed ID: 27608290
[TBL] [Abstract][Full Text] [Related]
50. Production and tumour uptake of [64Cu]Pyruvaldehyde-bis (N4-methylthiosemicarbazone) for PET and/or therapeutic purposes.
Jalilian AR; Rowshanfarzad P; Kamrani YY; Shafaii K; Mirzaii M
Nucl Med Rev Cent East Eur; 2007; 10(1):6-11. PubMed ID: 17694494
[TBL] [Abstract][Full Text] [Related]
51. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies.
Liu S; Li D; Park R; Liu R; Xia Z; Guo J; Krasnoperov V; Gill PS; Li Z; Shan H; Conti PS
J Nucl Med; 2013 Jul; 54(7):1094-100. PubMed ID: 23667241
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of a potential generator-produced PET tracer for cerebral perfusion imaging: single-pass cerebral extraction measurements and imaging with radiolabeled Cu-PTSM.
Mathias CJ; Welch MJ; Raichle ME; Mintun MA; Lich LL; McGuire AH; Zinn KR; John EK; Green MA
J Nucl Med; 1990 Mar; 31(3):351-9. PubMed ID: 2308007
[TBL] [Abstract][Full Text] [Related]
53. In vivo evaluation of (64)Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent.
Glaus C; Rossin R; Welch MJ; Bao G
Bioconjug Chem; 2010 Apr; 21(4):715-22. PubMed ID: 20353170
[TBL] [Abstract][Full Text] [Related]
54. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts.
Paudyal B; Paudyal P; Oriuchi N; Hanaoka H; Tominaga H; Endo K
Cancer Sci; 2011 Jan; 102(1):117-21. PubMed ID: 21070475
[TBL] [Abstract][Full Text] [Related]
55. Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64.
Wadas TJ; Anderson CJ
Nat Protoc; 2006; 1(6):3062-8. PubMed ID: 17406569
[TBL] [Abstract][Full Text] [Related]
56.
Kang L; Rosenkrans ZT; Cai W
Methods Mol Biol; 2019; 1974():223-231. PubMed ID: 31099007
[TBL] [Abstract][Full Text] [Related]
57. 64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues.
Higashikawa K; Yagi K; Watanabe K; Kamino S; Ueda M; Hiromura M; Enomoto S
PLoS One; 2014; 9(11):e109866. PubMed ID: 25365349
[TBL] [Abstract][Full Text] [Related]
58. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice.
Cai W; Ebrahimnejad A; Chen K; Cao Q; Li ZB; Tice DA; Chen X
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):2024-36. PubMed ID: 17673999
[TBL] [Abstract][Full Text] [Related]
59. PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor.
Jacobson O; Li Q; Chen H; Niu G; Kiesewetter DO; Xu L; Cook K; Yang G; Dall'Acqua W; Tsui P; Peng L; Chen X
J Nucl Med; 2017 Nov; 58(11):1838-1844. PubMed ID: 28546337
[TBL] [Abstract][Full Text] [Related]
60. New Bifunctional Chelator p-SCN-PhPr-NE3TA for Copper-64: Synthesis, Peptidomimetic Conjugation, Radiolabeling, and Evaluation for PET Imaging.
Gai Y; Sun L; Hui W; Ouyang Q; Anderson CJ; Xiang G; Ma X; Zeng D
Inorg Chem; 2016 Jul; 55(14):6892-901. PubMed ID: 27347690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
